Q3: Multiple First Approvals for Gene, RNA Therapies

ASGCT Staff - October 21, 2022

More gene and RNA therapies were approved in Q3 than in each of the previous quarters for over a year.

The third quarterly report of 2022 from ASGCT and Citeline (formerly Informa Pharma Intelligence) is available now! The Gene, Cell, & RNA Therapy Landscape report is the only field-wide report covering the therapeutics pipeline, clinical targets, developer progress, and more.

Highlights from this issue include:

  • Approval of two gene therapies in the EU and two more in the U.S.

  • CAR T-cell therapy continuing to dominate the pipeline of genetically modified cell therapies

  • An increase of 11 percent in dealmaking and jumps in partnerships and fundraising

Download the Full Report

Click any of the samples below to view the full report: